Marshall Wace LLP purchased a new stake in Cara Therapeutics Inc (NASDAQ:CARA) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 348,926 shares of the biopharmaceutical company’s stock, valued at approximately $6,682,000. Marshall Wace LLP owned approximately 0.89% of Cara Therapeutics at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Exane Derivatives acquired a new stake in Cara Therapeutics in the 2nd quarter valued at about $138,000. BB&T Securities LLC acquired a new stake in Cara Therapeutics in the 2nd quarter valued at about $218,000. Raymond James & Associates acquired a new stake in Cara Therapeutics in the 2nd quarter valued at about $250,000. DekaBank Deutsche Girozentrale acquired a new stake in Cara Therapeutics in the 1st quarter valued at about $164,000. Finally, Cornerstone Wealth Management LLC acquired a new stake in Cara Therapeutics in the 2nd quarter valued at about $715,000. 48.66% of the stock is currently owned by institutional investors.
In other Cara Therapeutics news, SVP Frederique Ph.D. Menzaghi sold 3,000 shares of Cara Therapeutics stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $18.89, for a total value of $56,670.00. Following the transaction, the senior vice president now directly owns 101,000 shares in the company, valued at approximately $1,907,890. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Derek T. Chalmers sold 20,000 shares of Cara Therapeutics stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $23.79, for a total value of $475,800.00. The disclosure for this sale can be found here. Insiders sold a total of 49,000 shares of company stock worth $1,058,070 over the last quarter. Company insiders own 6.70% of the company’s stock.
NASDAQ:CARA opened at $20.20 on Tuesday. The company has a market cap of $941.01 million, a P/E ratio of -10.86 and a beta of 2.88. Cara Therapeutics Inc has a 52-week low of $11.11 and a 52-week high of $24.30.
Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The company had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $0.63 million. As a group, analysts expect that Cara Therapeutics Inc will post -2.01 earnings per share for the current fiscal year.
About Cara Therapeutics
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Featured Story: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.